MAP2K7 and metastatic melanoma: The SECOMBIT phase II trial explored the optimal sequential treatment for metastatic melanoma patients: BRAF/MEK inhibitors as the first line followed by immunotherapy, or immunotherapy as the first line followed by BRAF/MEK inhibitors [101].